
Gubra’s AbbVie-partnered amylin looks competitive with Zealand’s in early trial
GUBamy, the amylin obesity candidate developed by Gubra and licensed to AbbVie for $350 million last month, demonstrated encouraging weight loss in … Sign up to read this article for free. Get free access to a limited number of articles, …